45 results on '"Steg, Ph. Gabriel"'
Search Results
2. Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study
3. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl
4. Lipoprotein(a) and the Effect of Alirocumab on Revascularization After Acute Coronary Syndrome
5. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF
6. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes
7. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT
8. Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI
9. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
10. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
11. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19
12. Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program
13. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
14. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
15. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial
16. Prevalence and Outcomes of Polyvascular (Coronary, Peripheral, or Cerebrovascular) Disease in Patients With Diabetes Mellitus (From the SAVOR-TIMI 53 Trial)
17. Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events)
18. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease
19. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)
20. Hemoglobin and Change in Hemoglobin Status Predict Mortality, Cardiovascular Events, and Bleeding in Stable Coronary Artery Disease
21. Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial
22. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up
23. Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])
24. NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease
25. Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab
26. Adherence to Secondary Prevention Medications and Four-year Outcomes in Outpatients with Atherosclerosis
27. Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes)
28. An International Model to Predict Recurrent Cardiovascular Disease
29. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT
30. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy
31. Ethnic Differences in Cardiovascular Risks and Mortality in Atherothrombotic Disease: Insights From the REduction of Atherothrombosis for Continued Health (REACH) Registry
32. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)
33. Causes and Risk Factors for Death in Diabetes: A Competing-Risk Analysis From the SAVOR-TIMI 53 Trial
34. Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention: 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial
35. Prehospital Delay in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events [GRACE])
36. Thrombocytopenia in Patients With an Acute Coronary Syndrome (from the Global Registry of Acute Coronary Events [GRACE])
37. A Randomized Comparison of High Clopidogrel Loading Doses in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: The ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) Trial
38. Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles
39. REDUCTION IN HEART FAILURE WITH ICOSAPENT ETHYL: INSIGHTS FROM REDUCE-IT HF
40. ICOSAPENT ETHYL REDUCES ISCHEMIC EVENTS IN PATIENTS WITH HIGH TRIGLYCERIDES AND LOW HIGH-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS: REDUCE-IT HIGH TG/LOW HDL-C ANALYSES
41. Reply: Ischemic Event Reduction and Triglycerides
42. The Reply
43. REDUCTION IN ISCHEMIC EVENTS WITH TICAGRELOR IN DIABETIC PATIENTS FROM THE PEGASUS-TIMI 54 TRIAL
44. Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice
45. ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.